Type-I interferons in the immunopathogenesis and treatment of Coronavirus disease 2019.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19), is currently the major global health problem. Still, it continues to infect people globally and up to the end of February 2022, over 436 million confirmed cases of COVID-19, including 5.95 million deaths, were reported to the world health organization (WHO). No specific treatment is currently available for COVID-19, and the discovery of effective therapeutics requires understanding the effective immunologic and immunopathologic mechanisms behind this infection. Type-I interferons (IFN-Is), as the critical elements of the immediate immune response against viral infections, can inhibit the replication and spread of the viruses. However, the available evidence shows that the antiviral IFN-I response is impaired in patients with the severe form of COVID-19. Moreover, the administration of exogenous IFN-I in different phases of the disease can lead to various outcomes. Therefore, understanding the role of IFN-I molecules in COVID-19 development and its severity can provide valuable information for better management of this disease. This review summarizes the role of IFN-Is in the pathogenesis of COIVD-19 and discusses the importance of autoantibodies against this cytokine in the spreading of SARS-CoV-2 and control of the subsequent excessive inflammation. Copyright © 2022 Elsevier B.V. All rights reserved.

Citation

Hossein Khorramdelazad, Mohammad Hossein Kazemi, Maryam Azimi, Azin Aghamajidi, Ali Zarezadeh Mehrabadi, Faezeh Shahba, Nazanin Aghamohammadi, Reza Falak, Fatemeh Faraji, Reza Jafari. Type-I interferons in the immunopathogenesis and treatment of Coronavirus disease 2019. European journal of pharmacology. 2022 Jul 15;927:175051

Mesh Tags

Substances

PMID: 35618037

search → result